<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02914132</url>
  </required_header>
  <id_info>
    <org_study_id>CP001</org_study_id>
    <nct_id>NCT02914132</nct_id>
  </id_info>
  <brief_title>Safety Evaluation of Seraph® 100 to Reduce Bacteremia in Patients on Hemodialysis</brief_title>
  <official_title>Safety and Performance Evaluation of the Seraph® 100 Microbind® Affinity Blood Filter for Reducing Bacteremia in Patients on Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ExThera Medical Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ExThera Medical Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the Seraph® 100 Microbind® Affinity Blood
      Filter (Seraph 100) is safe in the treatment of dialysis patients with bacteremia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a prospective, non-randomized study in patients as an adjunctive treatment for
      blood stream infection (BSI) in patients on renal replacement therapy. The heparin surface
      being studied is currently marketed on extracorporeal circuits. It has been shown to absorb
      various types of Gram positive and Gram negative bacteria and to reduce toxins and cytokines
      in in vitro studies using whole blood. For this study, patients on renal replacement therapy
      who develop bacteremia will have the Seraph® 100 Microbind® Affinity Blood Filter included in
      the dialysis circuit for up to 4 hours, on one day, with hourly monitoring. Patients will be
      followed for 14 days post treatment. Patients will be monitored by vital signs and laboratory
      indices on the day of treatment and on post procedure day 1, 2, 3, 4, 5, 6, 7 and 14.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">June 7, 2018</completion_date>
  <primary_completion_date type="Actual">June 7, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Demonstrate Safety of the ExThera Medical Seraph® 100 Microbind® Affinity Blood Filter in a Hemodialysis Circuit Assessed by Rate of Adverse Events.</measure>
    <time_frame>14 days</time_frame>
    <description>Demonstrate safety of the ExThera Medical Seraph® 100 Microbind® Affinity Blood Filter in a hemodialysis circuit assessed by rate of adverse events. No adverse events occured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of Bacteria in Blood Passed Through the Seraph 100 Filter.</measure>
    <time_frame>4 hours</time_frame>
    <description>Pathogen reduction of &gt; 40 % as CFU/mL or an increase in time to positivity (TTP) of &gt; 22 minutes in blood passed through the Seraph 100 Filter</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Bacteremia</condition>
  <condition>Bacterial Infection</condition>
  <arm_group>
    <arm_group_label>Seraph 100 Filter</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Renal replacement patient with bacteremia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Seraph 100 Filter</intervention_name>
    <description>Treatment of renal replacement therapy patients with bacteremia.</description>
    <arm_group_label>Seraph 100 Filter</arm_group_label>
    <other_name>Seraph 100</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Require renal replacement therapy.

          2. Be ≥ 18 years old and ≤ 90 years old

          3. Positive blood culture and one of the following:

               1. Clinical evidence of a catheter exit site to tunnel infection as evidenced by
                  redness, tenderness or purulence.

               2. Bacteremia is proven with two separate blood cultures from independent vein
                  punctures.

               3. A blood culture with Staphylococcus aureus where the time to positivity is within
                  14 hours.

               4. Growth from a blood culture taken from the hemodialysis catheter 2 or more hours
                  before the growth of a blood culture drawn peripherally at the same time.

        Exclusion Criteria:

          1. Have an arteriovenous polytetrafluoroethylene (PTFE) graft.

          2. Lack of a commitment to full aggressive support.

          3. Have inability to maintain a minimum mean arterial pressure of ≥ 65 mm Hg despite
             vasopressor therapy and fluid resuscitation.

          4. Have had chest compressions as part of cardiopulmonary resuscitation (CPR)

          5. Have had an acute myocardial infarction (MI) within the past 3 months.

          6. Have had serious injury within 36 hours of screening.

          7. Have uncontrolled hemorrhage.

          8. Are not expected to live &gt; 14 days.

          9. Have malignancy and are not expected to live 42 days.

         10. Have neutropenia (absolute neutrophil count &lt;500 cells/µL).

         11. Have Child-Pugh Class C cirrhosis.

         12. Have New York Heart Association Class IV Heart Failure or an ejection fraction &lt;30%.

         13. Have known Antithrombin III deficiency.

         14. Have platelet count &lt;30,000/µL.

         15. Cannot have intravenous (IV) supplemental iron halted during trial period.

         16. Are currently involved in an investigational drug or device trial.

         17. Have been previously enrolled in this clinical trial.

         18. Next hemodialysis treatment will not take place for at least 24 hours after
             enrollment.

         19. Serious bleedings and clotting disorders, determined by blood transfusion of &gt; 2 units
             of packed red blood cells, or, An acute (48 h) hemoglobin decline of at least 2 g/dL,
             transfusion requirement of &gt;4 units over 48h, objective evidence of bleed, documented
             by physician.

         20. Breast feeding and pregnant women

         21. Contraindications for heparin sodium for injection are:

               1. Have heparin sensitivity

               2. Severe thrombocytopenia.

               3. With an uncontrolled active bleeding state, except when this is due to
                  disseminated intravascular coagulation

               4. In whom suitable blood coagulation tests, e.g. whole blood clotting time, partial
                  thromboplastin time, etc cannot be performed at appropriate intervals (this
                  contraindication refers to full-dose heparin; there is usually no need to monitor
                  coagulation parameters in patients receiving low-dose heparin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan T Kielstein, MD,FASN,FERA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Braunschweig</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Braunschweig</name>
      <address>
        <city>Braunschweig</city>
        <zip>38126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum-Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule-Hannover</name>
      <address>
        <city>Hannöver</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>September 22, 2016</study_first_submitted>
  <study_first_submitted_qc>September 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2016</study_first_posted>
  <results_first_submitted>June 27, 2019</results_first_submitted>
  <results_first_submitted_qc>June 27, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 12, 2019</results_first_posted>
  <last_update_submitted>June 27, 2019</last_update_submitted>
  <last_update_submitted_qc>June 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 19, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT02914132/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Seraph 100 Filter</title>
          <description>Renal replacement patient with bacteremia.
Seraph 100 Filter: Treatment of renal replacement therapy patients with bacteremia.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients enrolled in the study</population>
      <group_list>
        <group group_id="B1">
          <title>Seraph 100 Filter</title>
          <description>Renal replacement patient with bacteremia.
Seraph 100 Filter: Treatment of renal replacement therapy patients with bacteremia.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Demonstrate Safety of the ExThera Medical Seraph® 100 Microbind® Affinity Blood Filter in a Hemodialysis Circuit Assessed by Rate of Adverse Events.</title>
        <description>Demonstrate safety of the ExThera Medical Seraph® 100 Microbind® Affinity Blood Filter in a hemodialysis circuit assessed by rate of adverse events. No adverse events occured</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Seraph 100 Filter</title>
            <description>Renal replacement patient with bacteremia.
Seraph 100 Filter: Treatment of renal replacement therapy patients with bacteremia.</description>
          </group>
        </group_list>
        <measure>
          <title>Demonstrate Safety of the ExThera Medical Seraph® 100 Microbind® Affinity Blood Filter in a Hemodialysis Circuit Assessed by Rate of Adverse Events.</title>
          <description>Demonstrate safety of the ExThera Medical Seraph® 100 Microbind® Affinity Blood Filter in a hemodialysis circuit assessed by rate of adverse events. No adverse events occured</description>
          <units>Percent participants w adverse event</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction of Bacteria in Blood Passed Through the Seraph 100 Filter.</title>
        <description>Pathogen reduction of &gt; 40 % as CFU/mL or an increase in time to positivity (TTP) of &gt; 22 minutes in blood passed through the Seraph 100 Filter</description>
        <time_frame>4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Seraph 100 Filter</title>
            <description>Renal replacement patient with bacteremia.
Seraph 100 Filter: Treatment of renal replacement therapy patients with bacteremia.</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of Bacteria in Blood Passed Through the Seraph 100 Filter.</title>
          <description>Pathogen reduction of &gt; 40 % as CFU/mL or an increase in time to positivity (TTP) of &gt; 22 minutes in blood passed through the Seraph 100 Filter</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 hour treatment and 14 day followup</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Seraph 100 Filter</title>
          <description>Renal replacement patient with bacteremia.
Seraph 100 Filter: Treatment of renal replacement therapy patients with bacteremia.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr. Director of Regulatory and Clinical Affairs</name_or_title>
      <organization>ExThera Medical Corporation</organization>
      <phone>9258392079</phone>
      <email>erdie@extheramedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

